ATCC

Unlock genetic secrets with the ATCC Genome Portal! Protect your research with authentic reference genomes that are traceable to our credible biological materials. Become a Supporting Member! https://ow.ly/pmj750Sba6b #ATCCGenomePortal #genomic #bioinformatics

To my wonderful network of Communications professionals, we are hiring for a communications specialist to join my organization. Take a look at this amazing job opportunity.

World Hepatitis Day, observed on July 28, holds special significance as it coincides with the birthday of Nobel-prize-winning scientist Dr. Blumberg. Dr. Blumberg’s remarkable contributions to public health include the discovery of the hepatitis B virus (HBV) in 1967 and the invention of a blood test to detect the virus. Additionally, he developed the first HBV vaccine in 1969. This annual observance serves as a vital opportunity to raise awareness about viral hepatitis, which is caused by five different agents (hepatitis A-E viruses). Unfortunately, low vaccine coverage for HBV and challenges in detection have led to chronic infections in 350–400 million people worldwide, resulting in liver diseases such as cirrhosis, liver failure, and hepatocellular carcinoma. Notably, approximately 80% of patients undergoing long-term treatment with nucleoside analog inhibitors of HBV DNA polymerase will eventually develop resistance to the treatment. Therefore, ongoing screening for new antiviral drugs remains crucial for effective patient care. ATCC is supporting Hepatitis B virus research in various ways. The HepG2 cell line, made available through ATCC, is widely used for Hepatitis B research. In addition, ATCC has developed quantitative synthetic molecular standards for HBV to use as controls in molecular assays used for the detection and quantification of these viruses from clinical samples. In addition, the Biological and Emerging Infections Resources (BEI Resources), a NIAID-funded program managed by ATCC offers a series of seven stable HepG2 human hepatoma cell lines producing different genotypes of HBV). These cell lines, which represent genotypes of varying prevalence, distribution, disease progression, and treatment outcomes, are a crucial tool for researchers in studying intergenotypic differences in antiviral immunity, pathogenesis, and drug development. Learn more about the work of BEI here --> https://lnkd.in/eft5Cz2y

Panels of PCR-based tests have become crucial in studying pathogens and detecting infectious diseases, significantly enhancing diagnosis, treatment, and public health monitoring. These panels offer high sensitivity and specificity, allowing clinicians to tailor treatments and respond rapidly to infections. However, it’s not easy to develop. “Building such panels takes time and effort, and the key here is to use authenticated [microbial] strains,” says Leka Papazisi, ATCC Principal Scientist.     At ATCC, we provide the essential biomaterials, including “high-quality, quantified microbes, as well as native and synthetic nucleic acids,” that drive the development and validation of these crucial diagnostic tools. “These materials are fundamental to developing PCR panels for the development, validation, and performance monitoring of these systems,” says ATCC Senior Scientist James Budnick, Ph.D.    Our commitment to quality and innovation supports researchers worldwide in their fight against infectious diseases.     Discover more about our role in advancing PCR-based diagnostic panels in Biocompare: https://lnkd.in/ekgDHSYg    #PCR #diagnostics #publichealth  

#Vector-borne diseases account for a significant fraction of the global infectious disease burden. To support the development of novel detection methods, ATCC offers a wide range of #microorganisms and nucleic acids for prevalent diseases such as Zika, dengue, chikungunya, malaria, Lyme disease, and babesiosis. Browse our growing portfolio of vector-borne disease resources. https://ow.ly/gTGZ50Sa1In

The national parks are host to some of the harshest habitats on Earth. Research on the #microorganisms collected from these extreme environments has provided valuable insight into the origins of life and led to innovations in #biotechnology. Read our blog to learn more about the microbial strains isolated from national parks. https://ow.ly/xe4E50Sbaxy #CredibleConversations

Our #primarycells serve as essential tools for advancing life science research and drug discovery. We also offer a system of culture media and reagents designed to boost growth, maximize functionality, and maintain normal morphology for each primary cell type. See how our primary cell portfolio can take the guess work out of your research. https://ow.ly/M9Be50Sc0HN

Excited to share a highlight from CRYO2024!    Today, CRYO2024 keynote speaker, Dr. Ruth R Cheng, illuminated critical gaps in advanced biological models and limitations related to current preservation techniques. Dr. Cheng discussed ATCC’s investments in innovative preservation technologies and our partnerships with the research community. Together, we’re driving collaborative discovery mechanisms that are set to transform the cell-based drug discovery landscape.   #cryo2024 #AdvancedCellModels #Biopreservation #DrugDiscovery #cryopreservation #cellculture #cellculturetechniques

Ensuring the quality of water used in food and beverage production is essential. See our authenticated strains that can support your testing needs. https://ow.ly/Ikbb50SaZto #watertesting #waterquality

Exciting news! Dr. Ruth Cheng, Senior Vice President and General Manager, Research & Industrial Solutions, ATCC, will be the Plenary Speaker at CRYO2024! CRYO2024 is the 61st annual meeting hosted by the Society for Cryobiology. This year’s theme is “Engineering Cryobiology for Life and Sustainability.” The event will bring together over 350 delegates from 35 countries, including scientists, researchers, and industry professionals. Join us virtually or in Washington, D.C. from July 23-25, 2024 to hear Dr. Cheng’s insights and connect with fellow cryobiology enthusiasts! #CRYO2024 #Biopreservation #DrugDiscovery #ScienceCommunity https://lnkd.in/enWAeH5j